Other Biologic Drugs

  • Girolamo Pelaia
  • Alessandro Vatrella
  • Rosario Maselli
Chapter
First Online:

Abstract

Potentially suitable targets for antiasthma treatments also include other pro-inflammatory cytokines such as interleukin-9 (IL-9), granulocyte-macrophage colony-stimulating factor (GM-CSF) as well as interleukin-17 (IL-17) and interleukin-23 (IL-23) [1–4].

Keywords

Allergic Asthma Airway Epithelial Cell Bronchial Hyperresponsiveness Asthmatic Airway Mast Cell Proliferation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Pelaia G, Vatrella A, Maselli R. The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012;11:958–72.CrossRefPubMedGoogle Scholar
  2. 2.
    Gallelli L, Busceti MT, Vatrella A, et al. Update on anticytokine treatment for asthma. Biomed Res Int. 2013;2013:104315.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Chung KF. Targeting the interleukin pathway in the treatment of asthma. Lancet. 2015;386:1086–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Mitchell PD, El-Gammal A, O’Byrne PM. Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther. 2016;99:38–48.CrossRefPubMedGoogle Scholar
  5. 5.
    Xing J, Wu Y, Ni B. Th9: a new player in asthma pathogenesis? J Asthma. 2011;48:115–25.CrossRefPubMedGoogle Scholar
  6. 6.
    Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118:3546–56.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Cheng G, Arima M, Honda K, et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am J Respir Crit Care Med. 2002;166:409–16.CrossRefPubMedGoogle Scholar
  8. 8.
    Kearley J, Eriefalt JS, Andersson C, et al. IL-9 governs allergen-induced mast cell numbers in the lung and chronic remodelling of the airways. Am J Respir Crit Care Med. 2011;183:865–75.CrossRefPubMedGoogle Scholar
  9. 9.
    White B, Leon F, White W, Robbie G. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9 in healthy volunteers. Clin Ther. 2009;31:728–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Parker JM, Oh CK, LaForce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011;11:14.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Oh CK, Leigh R, McLaurin KK, et al. A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. Respir Res. 2013;14:93.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Yamashita N, Tashimo H, Ishida H, et al. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol. 2002;219:92–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Krinner EM, Raum T, Petsch S, et al. A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol. 2007;44:916–25.CrossRefPubMedGoogle Scholar
  14. 14.
    Molfino NA, Kuna P, Leff JA, et al. Phase 2, randomised placebo-controlled trial to evaluate the efficacy and safety of an anti-GM-CSF antibody (KB003) in patients with inadequately controlled asthma. BMJ Open. 2016;6:e007709.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Al Ramly W, Prefontaine D, Chouiali F, et al. T(H)17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123:1185–7.CrossRefGoogle Scholar
  16. 16.
    Vazquez-Tello A, Halwani R, Hamid Q, Al-Muhsen S. Glucocorticoid receptor-b up-regulation and steroid resistance induction by IL-17 and IL-23 cytokine stimulation in peripheral mononuclear cells. J Clin Immunol. 2013;33:466–78.CrossRefPubMedGoogle Scholar
  17. 17.
    Hellings PW, Kasran A, Liu Z, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol. 2003;28:42–50.CrossRefPubMedGoogle Scholar
  18. 18.
    Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188:1294–302.CrossRefPubMedGoogle Scholar
  19. 19.
    Wakashin H, Hirose K, Maezawa Y, et al. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med. 2008;178:1023–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Y, Sun M, Cheng H, et al. Silencing IL-23 expression by a small hairpin RNA protects against asthma in mice. Exp Mol Med. 2011;43:197–204.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Park SJ, Lee YC. Interleukin-17 regulation: an attractive therapeutic approach for asthma. Respir Res. 2010;11:78.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  • Girolamo Pelaia
    • 1
  • Alessandro Vatrella
    • 2
  • Rosario Maselli
    • 1
  1. 1.University “Magna Graecia”CatanzaroItaly
  2. 2.University of SalernoSalernoItaly

Personalised recommendations